Expanding the chemical space of ester of quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives as potential antitubercular agents†

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics MedChemComm Pub Date : 2024-07-17 DOI:10.1039/D4MD00221K
Alonzo González-González, Oscar Sánchez-Sánchez, Baojie Wan, Scott Franzblau, Isidro Palos, José C. Espinoza-Hicks, Adriana Moreno-Rodríguez, Ana Verónica Martínez-Vázquez, Edgar E. Lara-Ramírez, Eyra Ortiz-Pérez, Alma D. Paz-González and Gildardo Rivera
{"title":"Expanding the chemical space of ester of quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives as potential antitubercular agents†","authors":"Alonzo González-González, Oscar Sánchez-Sánchez, Baojie Wan, Scott Franzblau, Isidro Palos, José C. Espinoza-Hicks, Adriana Moreno-Rodríguez, Ana Verónica Martínez-Vázquez, Edgar E. Lara-Ramírez, Eyra Ortiz-Pérez, Alma D. Paz-González and Gildardo Rivera","doi":"10.1039/D4MD00221K","DOIUrl":null,"url":null,"abstract":"<p >Tuberculosis is a worldwide health problem that warrants attention given that the current treatment options require a long-term chemotherapeutic period and have reported the development of <em>Mycobacterium tuberculosis</em> (<em>M. tuberculosis</em>) multidrug resistant strains. In this study, <em>n</em>-butyl and isobutyl quinoxaline-7-carboxylate 1,4-di-<em>N</em>-oxide were evaluated against replicating and non-replicating H37Rv <em>M. tuberculosis</em> strains. The results showed that seventeen of the twenty-eight derivatives have minimum inhibitory concentration (MIC) values lower than isoniazid (2.92 μM). The most active antimycobacterial agents were <strong><strong>T-148</strong></strong>, <strong><strong>T-149</strong></strong>, <strong><strong>T-163</strong></strong>, and <strong><strong>T-164</strong></strong>, which have the lowest MIC values (0.53, 0.57, 0.53, and 0.55 μM respectively). These results confirm the potential of quinoxaline-1,4-di-<em>N</em>-oxide against <em>M. tuberculosis</em> to develop and obtain new and more safety antituberculosis drugs.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 8","pages":" 2785-2791"},"PeriodicalIF":3.5970,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00221k","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis is a worldwide health problem that warrants attention given that the current treatment options require a long-term chemotherapeutic period and have reported the development of Mycobacterium tuberculosis (M. tuberculosis) multidrug resistant strains. In this study, n-butyl and isobutyl quinoxaline-7-carboxylate 1,4-di-N-oxide were evaluated against replicating and non-replicating H37Rv M. tuberculosis strains. The results showed that seventeen of the twenty-eight derivatives have minimum inhibitory concentration (MIC) values lower than isoniazid (2.92 μM). The most active antimycobacterial agents were T-148, T-149, T-163, and T-164, which have the lowest MIC values (0.53, 0.57, 0.53, and 0.55 μM respectively). These results confirm the potential of quinoxaline-1,4-di-N-oxide against M. tuberculosis to develop and obtain new and more safety antituberculosis drugs.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
拓展喹喔啉-7-羧酸酯 1,4- 二-N-氧化物衍生物作为潜在抗结核药物的化学空间
结核病是一个世界性的健康问题,值得关注,因为目前的治疗方案需要长期的化疗,而且有报告称出现了结核分枝杆菌(M. tuberculosis)耐多药菌株。本研究评估了喹喔啉-7-甲酸正丁酯和喹喔啉-7-甲酸异丁酯 1,4-二-N-氧化物对复制和非复制 H37Rv 结核分枝杆菌菌株的作用。结果表明,28 种衍生物中有 17 种的最小抑菌浓度 (MIC) 值低于异烟肼(2.92 μM)。活性最强的抗霉菌剂是 T-148、T-149、T-163 和 T-164,它们的 MIC 值最低(分别为 0.53、0.57、0.53 和 0.55 μM)。这些结果证实了喹喔啉-1,4-二-N-氧化物抗结核杆菌的潜力,有助于开发和获得更安全的新型抗结核药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
期刊最新文献
Back cover Introduction to the themed collection in honour of Professor Christian Leumann Back cover Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy Introduction to the themed collection on ‘AI in Medicinal Chemistry’
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1